FGF2 and neoplasm: The tumour progression with these aberrant blood vessels develops hypoxia within the core and leads to the process “angiogenic switch” by classical regulators such as vascular endothelial growth factor receptors (VEGF-R), platelet derived growth factor receptor (PDGFR), fibroblast growth factor-2 (FGF-2), interleukins and angiopoietin (63).